At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 66 enrolled
Drug / intervention
Ruxolitinibdrug
Likely dose
Ruxolitinib 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label Assessment of Safety and Efficacy of Ruxolitinib (INCB018424) in Subjects With Primary Myelofibrosis, Post- Essential Thrombocythemia Myelofibrosis, and Post-Polycythemia Vera Myelofibrosis Who Have Platelet Counts of 50 × 10^9/L to 100 × 10^9/L
In Brief
A Phase 2 clinical trial evaluating Ruxolitinib for MPN (Myeloproliferative Neoplasms). Completed, enrolled 66 participants across 38 sites.
Detailed Summary
To evaluate the effects of treatment with ruxolitinib (INCB018424) on spleen volume, symptoms and potential side effects in participants with PMF, PPV-MF and PET-MF who have platelet counts of 50 x 10\^9/L to 100 x 10\^9/L. It is anticipated that individualized dose optimization from the starting ruxolitinib level of 5 mg bid will be associated with reductions in splenomegaly, MF-associated symptoms and inflammatory cytokine levels.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMPN (Myeloproliferative Neoplasms)
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMay 2011
Enrollment StartJun 2011
Primary CompletionDec 2018
TodayJul 2026
First PostedMay 5, 2011
Enrollment StartJun 15, 2011
Primary CompletionDec 19, 2018
TodayJul 2, 2026
Enrollment to primary: 7.5 yearsPosted 15.2 years ago
Interventions
Ruxolitinibdrug
Ruxolitinib (INCB018424), 5 mg bid